```html

Quincy Disease (Hypophosphatasia) – A Complete Medical Guide

Overview

Hypophosphatasia (HPP), sometimes called “Quincy disease” after the first family described in Quincy, Massachusetts, is a rare inherited metabolic disorder that results in deficient activity of the enzyme tissue‑non‑specific alkaline phosphatase (TNSALP). The enzyme’s role is to break down certain phosphate‑containing compounds; when it is lacking, inorganic pyrophosphate accumulates and interferes with normal bone and tooth mineralization.

• Who it affects: All ages, from infants (perinatal‑severe form) to adults. Both sexes are equally affected.
• Prevalence: Estimated at 1 in 100,000–300,000 live births worldwide; higher in certain isolated populations (e.g., some Native American groups) where carrier frequencies can reach 1 % [NIH, 2022].
• Inheritance: Autosomal recessive in most severe forms; autosomal dominant in milder adult‑onset disease. Mutations occur in the ALPL gene.

Symptoms

Symptoms vary dramatically based on the age of onset and the specific genetic mutation. The disease is classified into six clinical forms: perinatal‑severe, perinatal‑moderate, infantile, childhood, adult, and odontohypophosphatasia. Below is a comprehensive list with brief descriptions.

Perinatal‑Severe (in utero or at birth)

• Shortened limbs (micromelia) and bent bones (bowing).
• Thin, poorly mineralized skull (craniosynostosis is rare).
• Respiratory failure due to weak chest wall.
• Low alkaline phosphatase (ALP) levels in newborn screening.

Perinatal‑Moderate (survives birth)

• Similar skeletal abnormalities but less severe.
• Feeding difficulties, failure to thrive.
• Potential seizures from metabolic imbalance.

Infantile (typically 0‑6 months)

• Rickets‑like bone pain, fractures with minimal trauma.
• Loose teeth that fall out prematurely.
• Hypercalcemia (high blood calcium) leading to irritability, vomiting, constipation.
• Muscle weakness, poor motor milestones.

Childhood

• Progressive bone pain, especially in the lower limbs.
• Repeated fractures and pseudofractures (Looser zones).
• Delayed walking or waddling gait.
• Dental manifestations: premature loss of primary teeth, enamel defects.
• Potential short stature.

Adult-Onset

• Recurrent or chronic bone pain, especially in the hips, knees, and spine.
• Stress fractures and low‑impact fractures.
• Osteomalacia (softening of bone) visible on imaging.
• Metatarsal stress fractures causing foot pain.
• Dental issues are less common but may include early tooth loss.
• Potential muscle weakness and fatigue.

Odontohypophosphatasia (mildest form)

• Premature loss of primary (baby) teeth, often without other systemic signs.
• Enamel hypoplasia and dentin defects.
• Normal ALP for most other labs.

Causes and Risk Factors

Genetic Basis

The disease stems from pathogenic variants in the ALPL gene located on chromosome 1p36.3. The gene encodes TNSALP, essential for hydrolyzing inorganic pyrophosphate (PPi), phosphoethanolamine (PEA), and pyridoxal‑5′‑phosphate (PLP). Over 400 different mutations have been described, ranging from missense to nonsense and splice‑site changes.

Inheritance Patterns

• Autosomal recessive: Two defective copies are required. Most severe neonatal forms follow this pattern.
• Autosomal dominant: A single pathogenic allele can cause milder, adult‑onset disease. Variable penetrance means some carriers remain asymptomatic.

Risk Factors

• Having a sibling or parent with confirmed HPP.
• Consanguineous marriage (increased chance of recessive inheritance).
• Being part of a population with a known founder mutation (e.g., certain Amish communities).
• Maternal exposure to high‑dose vitamin D in pregnancy can exacerbate hypercalcemia in an infant with HPP.

Diagnosis

Because HPP mimics many other bone disorders, a systematic approach is essential.

Clinical Evaluation

• Detailed personal and family history, focusing on early tooth loss, fractures, and unexplained bone pain.
• Physical exam for skeletal deformities, gait abnormalities, and dental assessment.

Laboratory Tests

• Serum alkaline phosphatase (ALP): Usually low for age‑adjusted norms – the hallmark laboratory finding.
• Serum calcium & phosphorus: May be high, low, or normal; hypercalcemia common in infants.
• Vitamin D (25‑OH): Checked to rule out deficiency.
• Pyridoxal‑5′‑phosphate (PLP): Elevated in HPP because TNSALP cannot convert PLP to pyridoxine.
• Phosphoethanolamine (PEA) in urine: Elevated levels are supportive.

Genetic Testing

Sequencing of the ALPL gene confirms the diagnosis and clarifies inheritance pattern. Testing is recommended for the patient and, when relevant, for family members.

Imaging

• X‑rays: Show poorly mineralized bones, metaphyseal cupping, and Looser zones.
• Bone densitometry (DXA): Low bone mineral density, especially in adult‑onset disease.
• CT/MRI: Used for complex skeletal deformities or spinal involvement.

Diagnostic Criteria (adapted from the International Consensus 2019)

A diagnosis is established when any two of the following are present:

1. Low serum ALP for age.
2. Elevated urinary PEA or serum PLP.
3. Characteristic radiographic findings.
4. Confirmed pathogenic ALPL variant.
5. Family history consistent with HPP.

Treatment Options

Management has evolved dramatically with the introduction of enzyme‑replacement therapy (ERT). Treatment is individualized based on disease severity, age, and organ systems involved.

Enzyme Replacement Therapy – Asfotase Alfa

• Mechanism: A recombinant human TNSALP fused to a bone‑targeting domain.
• Indications: All patients with perinatal‑severe, perinatal‑moderate, infantile, and childhood forms; approved for adult HPP with functional impairment.
• Dosing: Subcutaneous injection 1–3 mg/kg three times per week (per label). Doses may be adjusted based on response and side effects.
• Efficacy: Clinical trials show improved survival in perinatal‑severe infants (from 30 % to >90 % 2‑year survival) and increased bone mineralization, reduced pain, and better mobility in children and adults (Mayo Clinic, 2021).
• Side effects: Injection‑site reactions, lipodystrophy, ectopic calcifications, and rare hypersensitivity.

Supportive & Symptomatic Care

• Calcium & Vitamin D: Use cautiously. In infants with hypercalcemia, low‑dose calcitriol may be required; excessive supplementation can worsen hypercalcemia.
• Pain management: Acetaminophen or NSAIDs as needed; consider neuropathic agents (gabapentin) for chronic pain.
• Orthopedic interventions: Surgical fixation for unstable fractures, corrective osteotomies for severe deformities, and spinal fusion when progressive scoliosis develops.
• Dental care: Early involvement of a pediatric dentist; use of removable prostheses or dental implants once bone quality permits.

Lifestyle & Rehabilitation

• Weight‑bearing exercise (low impact) to stimulate bone formation under supervision.
• Physical therapy focusing on gait training, balance, and core strengthening.
• Fall‑prevention strategies for adults (handrails, non‑slip footwear).

Living with Quincy disease (hypophosphatasia)

Living with HPP requires a multidisciplinary approach. Below are practical tips for patients, caregivers, and families.

Daily Management

• Track serum ALP and calcium levels regularly (every 3‑6 months for stable disease; more often after medication changes).
• Maintain a balanced diet rich in fruits, vegetables, and adequate protein; avoid high‑dose calcium supplements unless prescribed.
• Stay hydrated – adequate fluids help prevent kidney stones, a rare complication of hypercalcemia.
• Schedule routine dental check‑ups every 6 months.
• Use protective gear (kneepads, wrist guards) during physical activities to reduce fracture risk.

Emotional & Social Support

• Connect with patient advocacy groups such as the International Hypophosphatasia Foundation.
• Consider counseling or support groups to address chronic pain and anxiety.
• Schools and workplaces may need accommodations: extra time for mobility, ergonomic seating, or modified physical‑education requirements.

Monitoring for Complications

• Watch for signs of hypercalcemia (vomiting, constipation, irritability).
• In infants, monitor growth curves closely; poor weight gain may indicate malabsorption or metabolic imbalance.
• In adults, periodic DXA scans (every 1‑2 years) help gauge bone density trends.

Prevention

Because HPP is a genetic disorder, primary prevention relies on informed family planning.

• Genetic counseling: Recommended for couples with a known carrier status or a family history of HPP. Prenatal testing (chorionic villus sampling or amniocentesis) can identify affected fetuses.
• Carrier screening: Particularly advisable in high‑risk populations (e.g., certain Amish or Native American groups).
• Avoidance of triggers: In infants with known HPP, limit excess vitamin D supplementation and monitor calcium intake.

Complications

If left untreated or inadequately managed, HPP can lead to serious health problems.

• Respiratory insufficiency: Weak chest wall in perinatal‑severe disease can cause chronic ventilation problems.
• Severe hypercalcemia: May cause nephrocalcinosis, pancreatitis, or cardiac arrhythmias.
• Fractures and deformities: Repeated fractures can lead to permanent skeletal deformities, reduced mobility, and chronic pain.
• Dental complications: Early loss of teeth can affect nutrition, speech, and self‑esteem.
• Psychosocial impact: Chronic disease burden often leads to depression, anxiety, and reduced quality of life.
• Mortality: Historically high in perinatal‑severe forms; modern ERT has dramatically lowered infant mortality (<5 % 2‑year mortality in recent cohorts).

When to Seek Emergency Care

References

• Mayo Clinic. Hypophosphatasia – Symptoms & Causes. 2023.
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Hypophosphatasia. Updated 2022.
• International Consensus on Management of Hypophosphatasia, J. Bone Miner Res. 2019;34(4): 639‑652.
• Cleveland Clinic. Hypophosphatasia (HPP). 2022.
• World Health Organization. Rare Genetic Diseases. 2021.
• Thompson, D. et al. “Asfotase Alfa Therapy in Adults with Hypophosphatasia.” New England Journal of Medicine, 2021;384: 1044‑1055.

```